Nordhaven Pharma — Cold chain metro network
Lost$9.3m p.a. · 5 years · submitted Apr 2025
Model margin
9.8%
Contract value
$9.3m
per annum
Term
5 years
Submitted
Apr 2025
Summary
Temperature-controlled pharmaceutical distribution across three metro networks with GDP accreditation requirements.
Outcome — Lost on compliance scope — the GDP accreditation timeline was judged too slow. Costing assumptions were never tested in operation.